Journal Publications
Project Data Sphere's success is ultimately measured by the practice-changing scientific insights discovered by the research community. We are proud to share the following list of peer-accepted publications, and we are grateful to the data providers, research scientists, and patients that make this possible.
| Author(s) | Date |
Article Title |
Journal |
|---|---|---|---|
|
Omar Abdel-Rahman |
November 2019 | ECOG performance score 0 versus 1: impact on efficacy and safety of first-line 5-FU-based chemotherapy among patients with metastatic colorectal cancer included in five randomized trials | International Journal of Colorectal Disease |
|
Krastan B. Blagoev, Roumen Iordanov, Mengxi Zhou, Tito Fojo, Susan E. Bates |
January 2021 | Drug resistant cells with very large proliferative potential grow exponentially in metastatic prostate cancer | Oncotarget |
|
Aurélie Lombard, Hitesh Mistry, Leon Aarons, Kayode Ogungbenro |
October 2020 | Dose individualisation in oncology using chemotherapy‐induced neutropenia: Example of docetaxel in non‐small cell lung cancer patients | British Journal of Clinical Pharmacology |
|
Kaitlyn Johnson, Axel Gomez, Jackson Burton, Douglas White, Arijit Chakravarty, Annette Schmid, Dean Bottino |
November 2018 | Directional Inconsistency Between Response Evaluation Criteria in Solid Tumors (RECIST) Time to Progression and Response Speed and Depth | European Journal of Cancer |
|
Michael A. Webster-Clark, Hanna K. Sanoff, Til Stürmer, Sharon Peacock Hinton, Jennifer L. Lund |
January 2019 | Diagnostic Assessment of Assumptions for External Validity - An Example Using Data in Metastatic Colorectal Cancer | Epidemiology |
|
J. C. Angulo, J. P. Ciria Santos, A. Gómez-Caamaño, R. Poza de Celis, J. L. González Sala, J. M. García Garzón, J. A. Galán-Llopis, M. Pérez Sampietro, V. Perrot & J. Planas Morin on behalf of ANARESISTANCE study group |
September 2022 | Development of castration resistance in prostate cancer patients treated with luteinizing hormone-releasing hormone analogues (LHRHa): results of the ANARESISTANCE study | SpringerLink |
|
Tao Wang, Rong Lu, Sunny Lai, Joan H. Schiller, Fang Liz Zhou, Bo Ci, Stacy Wang, Xiaohan Gao, Bo Yao, David E. Gerber, David H. Johnson, Guanghua Xiao, Yang Xie |
February 2019 | Development and Validation of a Nomogram Prognostic Model for Patients with Advanced Non-Small-Cell Lung Cancer | Cancer Informatics |
|
Kirit Singh, Kristen A. Batich, Patrick Y. Wen, Aaron C. Tan, Stephen J. Bagley, Michael Lim, Michael Platten, Howard Colman, David M. Ashley, Susan M. Chang, Rifaquat Rahman, Evanthia Galanis, Alireza Mansouri, Vinay K. Puduvalli, David A. Reardon, Solmaz Sahebjam, John H. Sampson, John Simes, Donald A. Berry, Gelareh Zadeh, Tim F. Cloughesy, Minesh P. Mehta, Steven Piantadosi,Michael Weller, Amy B. Heimberger |
September 2021 | Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma | American Association for Cancer Research |
|
Stephen B. Cohen, Jennifer Unangst |
September 2018 | Data Integration Innovations to Enhance Analytic Utility of Clinical Trial Content to Inform Health Disparities Research | Frontiers in Oncology |
|
Mika Murtojarvia, Anni S. Halkolab, Antti Airolaa, Teemu D. Laajala, Tuomas Mirttid, Tero Aittokalliob, Tapio Pahikkalaa |
January 2020 | Cost-effective survival prediction for patients with advanced prostate cancer using clinical trial and real-world hospital registry datasets | International Journal of Medical Informatics |
|
Amanda C Guidon, Leeann B Burton, Bart K Chwalisz, James M Hillis, Teilo Schaller, Kerry Lynn Reynolds, Neuro irAE Disease Definition Panel |
May 2021 | Consensus disease definitions for the spectrum of neurologic immune related adverse events | Journal of Clinical Oncology |
|
Amanda C Guidon, Leeann B Burton, Bart K Chwalisz, James Hillis, Teilo H Schaller, Anthony A Amato, Allison Betof Warner, Priscilla K Brastianos, Tracey A Cho, Stacey L Clardy, Justine V Cohen, Jorg Dietrich, Michael Dougan, Christopher T Doughty, Divyanshu Dubey, Jeffrey M Gelfand, Jeffrey T Guptill, Douglas B Johnson, Vern C Juel, Robert Kadish, Noah Kolb, Nicole R LeBoeuf, Jenny Linnoila, Andrew L Mammen, Maria Martinez-Lage, Meghan J Mooradian, Jarushka Naidoo, Tomas G Neilan, David A Reardon, Krista M Rubin, Bianca D Santomasso, Ryan J Sullivan, Nancy Wang, Karin Woodman, Leyre Zubiri, William C Louv, Kerry L Reynolds |
July 2021 | Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors | Journal for ImmunoTherapy of Cancer |
|
Omar Abdel-Rahman |
March 2019 | Comparison of outcomes of radiotherapy-treated localized prostate cancer patients within a clinical trial setting versus real-life setting | Future Oncology |
|
Angela K. Green, Robert W. Corty, William A. Wood, Mathew Meeneghan, Katherine E. Reeder-Hayes, Ethan Basch, Matthew I Milowsky, Stacie B. Dusetzina |
May 2015 | Comparative Effectiveness of Mitoxantrone plus Prednisone versus Prednisone alone in Metastatic Castrate-resistant Prostate Cancer after Docetaxel Failure | The Oncologist |
